002550.SHE Changzhou Qianhong Biopharma Co Ltd
- Market cap
- CNY 7.74B
- P/E
- 33.6x
- P/B
- 2.76x
- ROE
- 10.2%
- Dividend yield
- 1.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002550.SHE undervalued?
Graham number002550.SHE trades 103.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Changzhou Qianhong Biopharma Co Ltd fundamental analysis
No fundamental analysis for Changzhou Qianhong Biopharma Co Ltd yet.
Changzhou Qianhong Biopharma Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase, as well as offers berry source and target diet box. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its…
Full company profileChangzhou Qianhong Biopharma Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Changzhou Qianhong Biopharma Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 776M | 1.07B | 1.32B | 1.68B | 1.67B | 1.87B | 2.30B | 1.81B | 1.53B | 1.57B | 1.54B |
| Gross Profit | 500M | 547M | 642M | 798M | 787M | 829M | 884M | 769M | 830M | 917M | 819M |
| Operating Income | 261M | 213M | 252M | 300M | -165M | 209M | 360M | 204M | 396M | 333M | 305M |
| EBITDA | 185M | 183M | 183M | 303M | 280M | 222M | 287M | 231M | 347M | 517M | 306M |
| Net Income | 224M | 183M | 221M | 263M | -132M | 181M | 323M | 182M | 356M | 399M | 287M |
| EPS | 0.18 | 0.14 | 0.17 | 0.21 | -0.11 | 0.14 | 0.25 | 0.14 | 0.28 | 0.31 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 3.03B | 3.04B | 3.18B | 2.93B | 2.45B | 2.51B | 2.81B | 2.77B | 2.83B | 3.09B | 3.24B |
| Total Liabilities | 609M | 591M | 640M | 602M | 386M | 390M | 373M | 292M | 314M | 321M | 454M |
| Shareholders' Equity | 2.40B | 2.44B | 2.53B | 2.33B | 2.08B | 2.13B | 2.45B | 2.45B | 2.52B | 2.77B | 2.80B |
| Cash & Short-term Investments | 146M | 186M | 420M | 866M | 750M | 686M | 477M | 713M | 714M | 491M | 602M |
| Total Debt | 373M | 384M | 432M | 344M | 41.9M | 89.5M | 100M | 55.6M | 20.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 221M | 88.5M | 25.4M | 162M | 317M | 104M | -71.5M | 533M | 515M | 361M | - |
| Capital Expenditure | 139M | 87.6M | 104M | 101M | 62.5M | 90.4M | 71.0M | 100M | 90.6M | 142M | 138M |
| Free Cash Flow | 82.1M | 892K | -78.1M | 60.9M | 255M | 13.2M | -142M | 433M | 424M | 220M | 210M |
| Ratios | |||||||||||
| ROE | 9.4% | 7.5% | 8.7% | 11.3% | -6.3% | 8.5% | 13.2% | 7.4% | 14.1% | 14.4% | 10.2% |
| ROA | 7.4% | 6.0% | 7.0% | 8.9% | -5.4% | 7.2% | 11.5% | 6.6% | 12.6% | 12.9% | 8.9% |
| Net Profit Margin | 28.9% | 17.2% | 16.7% | 15.7% | -7.9% | 9.7% | 14.0% | 10.0% | 23.3% | 25.4% | 18.6% |
| Debt to Equity | 0.16x | 0.16x | 0.17x | 0.15x | 0.02x | 0.04x | 0.04x | 0.02x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Changzhou Qianhong Biopharma Co Ltd dividends
- Dividend yield
- 1.94%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 37.7%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 150M | 0.12 | 37.7% |
| 2024 | CNY 152M | 0.12 | 42.6% |
| 2023 | CNY 153M | 0.12 | 84.1% |
| 2022 | CNY 150M | 0.12 | 46.4% |
| 2021 | CNY 150M | 0.12 | 82.8% |
| 2020 | CNY 304M | 0.24 | - |
| 2019 | CNY 153M | 0.12 | 58.2% |
| 2018 | CNY 124M | 0.10 | 55.9% |
| 2017 | CNY 118M | 0.09 | 64.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 31, 2016.
Who owns Changzhou Qianhong Biopharma Co Ltd
- Insiders 41.64%
- Institutions 1.97%
- Public & others 56.39%
- Shares outstanding 1.28B
- Free float 775M
Changzhou Qianhong Biopharma Co Ltd company profile
- Company name
- Changzhou Qianhong Biopharma Co Ltd
- Ticker
- 002550.SHE
- ISIN
- CNE100001070
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Feb 18, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,038
- Fiscal year end
- December
- Address
- Life and Health Industrial Park, Changzhou, China, 213125
- Phone
- 86 519 8515 6026
- Website
- qhsh.com.cn
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase, as well as offers berry source and target diet box. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its products. The company was founded in 1971 and is headquartered in Changzhou, China.
Changzhou Qianhong Biopharma Co Ltd management
9- Mr. Ke WangGM & Non-Independent Director · born 1983
- Mr. Yi YaoCFO & Board Secretary · born 1982
- Mr. Xiang ZhouDeputy GM & Non-Independent Director · born 1982
- Mr. Chizhou JiangNon-Independent Director & Deputy GM · born 1990
- Mr. Tao HaiDeputy General Manager · born 1969
- Ms. Aiqun XiaoAudit Director · born 1972
- Mr. Lijun WeiDirector · born 1972
- Ms. Jie HuangDirector · born 1987
- Mr. Guming WangDirector & GM of Production Center · born 1985